MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.numecd.2021.07.028

Медицинская библиотека · Nutrition, metabolism, and cardiovascular diseases : NMCD · 2021

Randomized trial of vitamin D versus placebo supplementation on markers of systemic inflammation in hypertensive patients.

Grübler Martin R, Zittermann Armin, Verheyen Nicolas D, Trummer Christian, Theiler-Schwetz Verena, Keppel Martin H, Malle Oliver, Richtig Georg, Gängler Stephanie, Bischoff-Ferrari Heike, Scharnagl Hubert, Meinitzer Andreas, März Winfried, Tomaschitz Andreas, Pilz Stefan

СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND AND AIMS: Animal and cell models indicated that vitamin D modulates inflammatory activity, which is considered relevant in the pathogenesis of arterial hypertension and cardiovascular diseases. We therefore aimed to investigate the effect of vitamin D supplementation on systemic markers of inflammation in a cohort of hypertensive patients.

METHODS AND

RESULTS

The Styrian Vitamin D Hypertension Trial is a single-centre, double-blind, placebo-controlled study conducted from 2011 to 2014 in Austria. We enrolled 200 study participants with arterial hypertension and 25-hydroxy-vitamin-D (25(OH)D) concentration below 30 ng/mL. Study participants were randomized to receive either 2800 IU of vitamin D3 per day or placebo for 8 weeks. The present investigation is a post-hoc analysis using analysis of co-variance (ANCOVA). Outcome measures were biomarkers of inflammation including CRP, leukocytes including subtypes and leukocyte-to-lymphocyte ratio, leucine and kynurenic acid. A total of 187 participants (mean age 60.1 ± 11.3years; 47% women; mean baseline 25(OH)D 21.1 ± 5.6 ng/mL) completed the trial. ANCOVA revealed a mean treatment effect for none of the respective outcomes and no significant results were detected in various subgroup analyses.

CONCLUSION

Vitamin D3 supplementation in hypertensive patients with insufficient 25(OH)D concentrations has no significant effect on lowering markers of systemic inflammation. Further studies investigating the effect of vitamin D on other inflammatory pathways and in populations with severe vitamin D deficiency and a significant inflammatory burden are required.

REGISTRATION: ClinicalTrials.gov Identifier: NCT02136771; EudraCT No. 2009-018,125-70. Start Date: 2011-04-06.

Для цитирования: Grübler Martin R, Zittermann Armin, Verheyen Nicolas D, Trummer Christian, Theiler-Schwetz Verena, Keppel Martin H, Malle Oliver, Richtig Georg, Gängler Stephanie, Bischoff-Ferrari Heike, Scharnagl Hubert, Meinitzer Andreas, März Winfried, Tomaschitz Andreas, Pilz Stefan. Randomized trial of vitamin D versus placebo supplementation on markers of systemic inflammation in hypertensive patients.. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2021. DOI: 10.1016/j.numecd.2021.07.028.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.